CREBBP and diffuse large B-cell lymphoma: Specifically, missense mutations in EZH2, DEAD-box helicase 3 X-linked (DDX3X), and lysine methyltransferase 2D (KMT2D), as well as both missense and truncating mutations in CREB-binding protein (CREBBP) and TP53, point toward different clinical features of the corresponding DLBCL subjects [30].